Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.

AIM To assess the efficacy of low-dose intermittent interferon (IFN) therapy in patients with hepatitis C virus (HCV)-related compensated cirrhosis who had received curative treatment for primary hepatocellular carcinoma (HCC). METHODS We performed a prospective case controlled study. Sixteen patients received 3 MIU of natural IFN-alpha intramuscularly 3 times weekly for at least 48 wk (IFN group). They were compared with 16 matched historical controls (non-IFN group). RESULTS The cumulative rate of first recurrence of HCC was not significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 68.6% vs 80% at 1- and 3-year, P = 0.157, respectively). The cumulative rate of second recurrence was not also significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 35.9% vs 67% at 1- and 3-year, P = 0.056, respectively). Although the difference in the Child-Pugh classification score between the groups at initial treatment of HCC was not significant, the score was significantly worse at the time of data analysis in the non-IFN group than IFN group (7.19 +/- 1.42 vs 5.81 +/- 0.75, P = 0.0008). The cumulative rate of deviation from objects of any treatment for recurrent HCC was also higher in the non-IFN group than IFN group (6.7% and 27% vs 0 and 0% at 1- and 3-year, P = 0.048, respectively). CONCLUSION Low-dose intermittent IFN-alpha therapy for patients with HCV-related compensated cirrhosis after curative HCC treatment was effective by making patients tolerant to medical or surgical treatment for recurrent HCC in the later period of observation.

[1]  L. Mariani,et al.  Prevention of hepatocellular carcinoma recurrence with alpha‐interferon after liver resection in HCV cirrhosis , 2006, Hepatology.

[2]  T. Kawabe,et al.  Sustained viral response prolonged survival of patients with C‐viral hepatocellular carcinoma , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[3]  坂口 康浩.  Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma , 2006 .

[4]  Liver Cancer Study Group of Japan.  The general rules for the clinical and pathological study of primary liver cancer , 2006, The Japanese journal of surgery.

[5]  G. Everson.  Management of cirrhosis due to chronic hepatitis C. , 2005, Journal of hepatology.

[6]  A. Tamori,et al.  Effect of Long-Term Postoperative Interferon Therapy on Intrahepatic Recurrence and Survival Rate after Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma , 2005, Intervirology.

[7]  M. Kudo,et al.  Low-Dose, Long-Term, Intermittent Interferon-alpha-2b Therapy after Radical Treatment by Radiofrequency Ablation Delays Clinical Recurrence in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma , 2005, Intervirology.

[8]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[9]  Y. Liaw,et al.  Prospective randomized controlled study of interferon‐alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors , 2004, Cancer.

[10]  Y. Shiratori,et al.  Interferon Therapy after Tumor Ablation Improves Prognosis in Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus , 2003, Annals of Internal Medicine.

[11]  S. Kubo,et al.  Randomized clinical trial of long‐term outcome after resection of hepatitis C virus‐related hepatocellular carcinoma by postoperative interferon therapy , 2002, The British journal of surgery.

[12]  H. Kawasaki,et al.  Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. , 2001, Hepatology research : the official journal of the Japan Society of Hepatology.

[13]  A. Tamori,et al.  Effects of Long-Term Postoperative Interferon- Therapy on Intrahepatic Recurrence after Resection of Hepatitis C VirusRelated Hepatocellular Carcinoma , 2001, Annals of Internal Medicine.

[14]  A. Tamori,et al.  Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. , 2001, Annals of internal medicine.

[15]  J. Reichen,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.

[16]  K. Chayama,et al.  Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—A prospective randomized study of hepatitis C virus–related liver cancer , 2000, Hepatology.

[17]  M. Sata,et al.  Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy , 2000, Annals of Internal Medicine.

[18]  oseph,et al.  PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS , 2000 .

[19]  G. Everson,et al.  Efficacy of interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhotics, fibrotics, or nonfibrotics , 1999, Hepatology.

[20]  P. Marcellin,et al.  Treatment of hepatitis C virus–related cirrhosis: A randomized, controlled trial of interferon alfa‐2b versus no treatment , 1999, Hepatology.

[21]  K. Wakasa,et al.  Effects of Continuous Hepatitis with Persistent Hepatitis C Viremia on Outcome after Resection of Hepatocellular Carcinoma , 1999, Japanese journal of cancer research : Gann.

[22]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[23]  P. Schmid,et al.  Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection? , 1998, Journal of hepatology.

[24]  O. Chazouilleres,et al.  Determinants of outcome of compensated hepatitis C virus‐related cirrhosis , 1998, Hepatology.

[25]  P. Marcellin,et al.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.

[26]  G. Fattovich,et al.  Therapy of hepatitis C: Patients with cirrhosis , 1997, Hepatology.

[27]  J. Hoofnagle,et al.  Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. , 1997, Gastroenterology.

[28]  H. Toyoda,et al.  Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma , 1997, Hepatology.

[29]  K. Shirabe,et al.  Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. , 1996, Gastroenterology.

[30]  A. Pezzoli,et al.  Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. , 1996, Journal of hepatology.

[31]  Y. Shiratori,et al.  Characteristic difference of hepatocellular carcinoma between hepatitis B‐ and C‐ viral infection in Japan , 1995, Hepatology.

[32]  O. Yokosuka,et al.  Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients , 1995, Hepatology.

[33]  X. Causse,et al.  Interferon‐α2b therapy reduces liver fibrosis in chronic non‐A, non‐B hepatitis: A quantitative histological evaluation , 1993, Hepatology.

[34]  T Nakamura,et al.  Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. , 1993, Gastroenterology.

[35]  H. Tsukuma,et al.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease. , 1993, The New England journal of medicine.

[36]  K. Chayama,et al.  Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma , 1993, Cancer.

[37]  Keiji Ueda,et al.  Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon‐α , 1992 .

[38]  N Hayashi,et al.  Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha. , 1992, Hepatology.

[39]  S. Baron,et al.  The interferons. Mechanisms of action and clinical applications. , 1991, JAMA.

[40]  K. Chayama,et al.  Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C , 1991, Hepatology.

[41]  J. Prieto,et al.  Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. , 1991, The New England journal of medicine.

[42]  J. Rosenbloom,et al.  Selective inhibition of human diploid fibroblast collagen synthesis by interferons. , 1984, The Journal of clinical investigation.